|
DZ2376A1
(fr)
*
|
1996-12-19 |
2002-12-28 |
Smithkline Beecham Plc |
Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
|
|
EP0994862B1
(en)
*
|
1997-07-11 |
2005-06-01 |
SmithKline Beecham plc |
Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
|
|
AU759255B2
(en)
|
1998-01-29 |
2003-04-10 |
Amgen, Inc. |
PPAR-gamma modulators
|
|
GB9803411D0
(en)
*
|
1998-02-18 |
1998-04-15 |
Smithkline Beecham Plc |
Novel compounds
|
|
US6194410B1
(en)
|
1998-03-11 |
2001-02-27 |
Hoffman-La Roche Inc. |
Pyrazolopyrimidine and pyrazolines and process for preparation thereof
|
|
GB9810671D0
(en)
*
|
1998-05-18 |
1998-07-15 |
Pfizer Ltd |
Anti-pruritic agents
|
|
GB9818916D0
(en)
|
1998-08-28 |
1998-10-21 |
Smithkline Beecham Plc |
Use
|
|
GB9818914D0
(en)
*
|
1998-08-28 |
1998-10-21 |
Smithkline Beecham Plc |
Use
|
|
GB9820113D0
(en)
|
1998-09-15 |
1998-11-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US7041691B1
(en)
|
1999-06-30 |
2006-05-09 |
Amgen Inc. |
Compounds for the modulation of PPARγ activity
|
|
GB9926302D0
(en)
*
|
1999-11-05 |
2000-01-12 |
Smithkline Beecham Plc |
Novel compounds
|
|
AU2441801A
(en)
*
|
1999-12-21 |
2001-07-03 |
Smithkline Beecham Corporation |
Urotensin-ii receptor antagonists
|
|
SE9904723D0
(sv)
*
|
1999-12-22 |
1999-12-22 |
Carlsson A Research Ab |
New modulators of dopamine neurotransmission II
|
|
SE0001899D0
(sv)
|
2000-05-22 |
2000-05-22 |
Pharmacia & Upjohn Ab |
New compounds
|
|
US20030171399A1
(en)
|
2000-06-28 |
2003-09-11 |
Tularik Inc. |
Quinolinyl and benzothiazolyl modulators
|
|
US6818639B2
(en)
|
2000-07-21 |
2004-11-16 |
Biovitrum Ab |
Pharmaceutical combination formulation and method of treatment with the combination
|
|
US6399617B1
(en)
|
2000-07-21 |
2002-06-04 |
Biovitrum Ab |
Use
|
|
SE0002739D0
(sv)
*
|
2000-07-21 |
2000-07-21 |
Pharmacia & Upjohn Ab |
New use
|
|
SE0002754D0
(sv)
*
|
2000-07-21 |
2000-07-21 |
Pharmacia & Upjohn Ab |
New pharmaceutical combination formulation and method of treatment with the combination
|
|
AU2001288053A1
(en)
*
|
2000-09-18 |
2002-03-26 |
Toa Eiyo Ltd. |
N-substituted benzothiophenesulfonamide derivatives
|
|
US7071220B2
(en)
|
2000-09-18 |
2006-07-04 |
Toa Eiyo Ltd. |
N-substituted benzothiophenesulfonamide derivatives
|
|
US7034029B2
(en)
|
2000-11-02 |
2006-04-25 |
Wyeth |
1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
|
|
US6849644B2
(en)
|
2000-11-21 |
2005-02-01 |
Smithkline Beecham P.L.C. |
Isoquinoline derivatives useful in the treatment of CNS disorders
|
|
EP1344525A4
(en)
|
2000-12-22 |
2005-05-25 |
Ishihara Sangyo Kaisha |
ANILINE DERIVATIVES OR ITS SALTS AND CYTOKINE PRODUCTION INHIBITORS CONTAINING THEM
|
|
JP2004534017A
(ja)
*
|
2001-04-27 |
2004-11-11 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ｂａｃｅのインヒビター
|
|
EP1387679A4
(en)
*
|
2001-05-07 |
2004-08-11 |
Smithkline Beecham Corp |
SULPHONAMIDES
|
|
AR033879A1
(es)
*
|
2001-05-07 |
2004-01-07 |
Smithkline Beecham Corp |
Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto
|
|
US6743796B2
(en)
*
|
2001-05-07 |
2004-06-01 |
Wyeth |
Piperazinyl-isatins
|
|
JP2004529168A
(ja)
*
|
2001-05-07 |
2004-09-24 |
スミスクライン・ビーチャム・コーポレイション |
スルホンアミド
|
|
EP1385495A4
(en)
*
|
2001-05-07 |
2005-12-21 |
Smithkline Beecham Corp |
SULPHONAMIDES
|
|
US6849635B2
(en)
*
|
2001-05-07 |
2005-02-01 |
Smithkline Beecham Corporation |
Sulfonamides
|
|
GB0111186D0
(en)
*
|
2001-05-08 |
2001-06-27 |
Smithkline Beecham Plc |
Novel compounds
|
|
US7718650B2
(en)
|
2001-05-11 |
2010-05-18 |
Biovitrum Ab |
Aryl sulfonamide compounds for treating obesity
|
|
NZ528450A
(en)
|
2001-05-11 |
2006-02-24 |
Biovitrum Ab |
Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders
|
|
RS88803A
(sr)
*
|
2001-05-11 |
2007-02-05 |
Biovitrum Ab., |
Nova jedinjenja arilsulfonamida za lečenje gojaznosti, dijabetesa tipa ii i poremećaja cns
|
|
MXPA03011244A
(es)
|
2001-06-07 |
2004-02-27 |
Hoffmann La Roche |
Nuevos derivados de indol con afinidad por el receptor 5-ht6.
|
|
CN100457726C
(zh)
|
2001-06-11 |
2009-02-04 |
比奥维特罗姆股份公开公司 |
取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ⅱ型糖尿病的药物的应用
|
|
CA2450245A1
(en)
|
2001-06-15 |
2002-12-27 |
F. Hoffmann-La Roche Ag |
4-piperazinylindole derivatives with 5-ht6 receptor affinity
|
|
US6727264B1
(en)
*
|
2001-07-05 |
2004-04-27 |
Synaptic Pharmaceutical Corporation |
Substituted anilinic piperidines as MCH selective antagonists
|
|
EP1414442A1
(en)
*
|
2001-08-07 |
2004-05-06 |
Smithkline Beecham Plc |
3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
|
|
ES2316619T3
(es)
|
2001-08-10 |
2009-04-16 |
F. Hoffmann-La Roche Ag |
Derivados de arilsulfonilo con afinidad receptora de 5-ht 6.
|
|
DE60223936D1
(de)
|
2001-09-05 |
2008-01-17 |
Eisai R&D Man Co Ltd |
Mittel zur anregung des appetits und mittel zur behandlung von anorexie
|
|
SE0103644D0
(sv)
*
|
2001-11-01 |
2001-11-01 |
Astrazeneca Ab |
Therapeutic isoquinoline compounds
|
|
ATE429916T1
(de)
*
|
2001-11-09 |
2009-05-15 |
Biovitrum Ab Publ |
Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
|
|
EA200400707A1
(ru)
|
2001-11-22 |
2004-10-28 |
Биовитрум Аб |
Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
|
|
US7074788B2
(en)
|
2001-11-22 |
2006-07-11 |
Biovitrum Ab |
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
|
|
JP2005516903A
(ja)
*
|
2001-11-30 |
2005-06-09 |
エフ．ホフマン−ラ ロシュ アーゲー |
喘息の処置におけるｃｃｒ−３受容体拮抗物質として使用するためのピペラジン誘導体
|
|
US20070270432A1
(en)
*
|
2002-02-05 |
2007-11-22 |
James Hagan |
Novel Method
|
|
AU2003203148A1
(en)
*
|
2002-02-05 |
2003-09-02 |
High Point Pharmaceuticals, Llc |
Novel aryl- and heteroarylpiperazines
|
|
EP1495004A2
(en)
*
|
2002-02-13 |
2005-01-12 |
Glaxo Group Limited |
Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor ligands
|
|
AU2003215558A1
(en)
*
|
2002-02-13 |
2003-09-04 |
Glaxo Group Limited |
Benzenesulfonamide derivatives as antipsychotic agents
|
|
ES2260607T3
(es)
*
|
2002-02-13 |
2006-11-01 |
Glaxo Group Limited |
Derivados de 7-arilsulfonamido-2,3,4,5-tetrahidro-1h-benzo-diazepina con afinidad por los receptores 5-ht6 para el tratamiento de trastornos del snc.
|
|
US7452888B2
(en)
|
2002-03-27 |
2008-11-18 |
Glaxo Group Limited |
Quinoline derivatives and their use as 5-ht6 ligands
|
|
US20040142948A1
(en)
*
|
2002-05-07 |
2004-07-22 |
Dashyant Dhanak |
Sulfonamides
|
|
EA009982B1
(ru)
*
|
2002-05-13 |
2008-04-28 |
Ф. Хоффманн-Ля Рош Аг |
Производные бензоксазина в качестве модуляторов 5-нт-6, способ их получения, фармацевтические композиции, содержащие эти производные, и их применение
|
|
MXPA04012914A
(es)
*
|
2002-06-20 |
2005-03-31 |
Biovitrum Ab |
Nuevos compuestos utiles para el tratamiento de la obesidad, diabetes tipo ii y desordenes cns.
|
|
US7943639B2
(en)
*
|
2002-06-20 |
2011-05-17 |
Proximagen Limited |
Compounds
|
|
EP1897881A3
(en)
|
2002-06-20 |
2009-03-18 |
Biovitrum AB (publ) |
Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
|
|
CN1309384C
(zh)
|
2002-10-18 |
2007-04-11 |
弗·哈夫曼-拉罗切有限公司 |
具有5－ht6受体亲和性的4－哌嗪基苯磺酰基吲哚
|
|
AU2003295408A1
(en)
*
|
2002-11-06 |
2004-06-03 |
Smithkline Beecham Corporation |
Sulfonamides
|
|
AU2003291262A1
(en)
*
|
2002-11-06 |
2004-06-03 |
Smithkline Beecham Corporation |
Sulfonamides
|
|
EP1599468B1
(en)
|
2003-01-14 |
2007-10-03 |
Arena Pharmaceuticals, Inc. |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
|
US7153858B2
(en)
|
2003-01-31 |
2006-12-26 |
Epix Delaware, Inc. |
Arylpiperazinyl compounds
|
|
WO2004072087A2
(de)
*
|
2003-02-13 |
2004-08-26 |
Lanxess Deutschland Gmbh |
Metallkomplexe als lichtabsorbierende verbindungen in der informationsschicht von optischen datenträgern
|
|
AU2004212985B2
(en)
*
|
2003-02-20 |
2010-10-14 |
Encysive Pharmaceuticals Inc. |
Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
|
|
TWI289141B
(en)
|
2003-03-11 |
2007-11-01 |
Hoffmann La Roche F. Ag. |
Quinolinone derivatives and uses thereof
|
|
WO2004087654A2
(en)
*
|
2003-03-31 |
2004-10-14 |
Janssen Pharmaceutica N.V. |
Phospholipase c inhibitors for use in treating inflammatory disorders
|
|
US6946466B2
(en)
*
|
2003-04-10 |
2005-09-20 |
Schering Ag |
Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
|
|
US20040204422A1
(en)
*
|
2003-04-14 |
2004-10-14 |
Abbott Gmbh & Co. Kg. |
N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
|
|
BRPI0412263B1
(pt)
|
2003-07-22 |
2019-10-15 |
Arena Pharmaceuticals, Inc. |
Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
|
|
GB0320320D0
(en)
*
|
2003-08-29 |
2003-10-01 |
Glaxo Group Ltd |
Novel compounds
|
|
US7223761B2
(en)
|
2003-10-03 |
2007-05-29 |
Amgen Inc. |
Salts and polymorphs of a potent antidiabetic compound
|
|
SE0303480D0
(sv)
*
|
2003-12-19 |
2003-12-19 |
Biovitrum Ab |
Benzofuranes
|
|
WO2005058858A1
(en)
*
|
2003-12-19 |
2005-06-30 |
Biovitrum Ab |
Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
|
|
JP2008508221A
(ja)
|
2004-07-28 |
2008-03-21 |
グラクソ グループ リミテッド |
消化器疾患の治療に有用なピペラジン誘導体
|
|
CN102114244A
(zh)
|
2004-09-30 |
2011-07-06 |
弗·哈夫曼-拉罗切有限公司 |
治疗认知障碍的组合物和方法
|
|
CN101039904B
(zh)
|
2004-10-14 |
2014-09-24 |
Abbvie德国有限责任两合公司 |
适于治疗对于多巴胺d3受体调节有反应的病症的杂环化合物
|
|
WO2006040176A1
(en)
|
2004-10-14 |
2006-04-20 |
Abbott Gmbh & Co. Kg |
Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
|
|
WO2006062481A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Biovitrum Ab |
New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
|
|
EP1676841A1
(en)
*
|
2004-12-30 |
2006-07-05 |
Esteve Laboratorios Dr. Esteve S.A. |
Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments
|
|
KR100931928B1
(ko)
*
|
2005-01-12 |
2009-12-15 |
인제대학교 산학협력단 |
P25/cdk5 저해 화합물을 포함하는 퇴행성 뇌질환의 예방 및치료용 약학 조성물
|
|
CA2614116A1
(en)
|
2005-07-04 |
2007-01-11 |
Novo Nordisk A/S |
Novel medicaments
|
|
KR101016972B1
(ko)
|
2005-08-12 |
2011-02-25 |
수벤 라이프 사이언시스 리미티드 |
기능성 5-ｈｔ6 리간드인 아미노아릴 설폰아미드 유도체
|
|
WO2007020654A1
(en)
|
2005-08-16 |
2007-02-22 |
Suven Life Sciences |
An improved process for the preparation of losartan
|
|
EP1976495A2
(en)
*
|
2006-01-06 |
2008-10-08 |
Aarhus Universitet |
Compounds acting on the serotonin transporter
|
|
TW200808709A
(en)
|
2006-03-31 |
2008-02-16 |
Glaxo Group Ltd |
Novel compounds
|
|
JP2009534355A
(ja)
|
2006-04-19 |
2009-09-24 |
アボット ゲーエムベーハー ウント カンパニー カーゲー |
セロトニン５ｈｔ６受容体の調節に応答する障害を治療するために好適な複素環化合物
|
|
JP2009534354A
(ja)
*
|
2006-04-19 |
2009-09-24 |
アボット ゲーエムベーハー ウント カンパニー カーゲー |
セロトニン５ｈｔ６受容体の調節に応答する障害を治療するために好適な複素環アリールスルホン類
|
|
US8318927B2
(en)
|
2006-05-23 |
2012-11-27 |
High Point Pharmaceuticals, Llc |
6-(4-cyclopropylpiperazin-1-yl)-2′-methyl-[3, 4′]-bipyridine and its uses as a medicament
|
|
SI2079732T1
(sl)
|
2006-05-29 |
2012-03-30 |
High Point Pharmaceuticals Llc |
benzodioksol il ciklopropilpiperazin il piridazin njegove soli in solvati in njegova uporaba kot antagonist histaminskega receptorja H
|
|
US7906555B2
(en)
|
2006-10-26 |
2011-03-15 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
|
|
CA2670717C
(en)
|
2007-01-08 |
2012-01-10 |
Suven Life Sciences Limited |
5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands
|
|
AU2008204583A1
(en)
*
|
2007-01-10 |
2008-07-17 |
F. Hoffmann-La Roche Ag |
Sulfonamide derivatives as chymase inhibitors
|
|
CA2681034A1
(en)
|
2007-03-23 |
2008-10-02 |
Abbott Gmbh & Co. Kg |
Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
|
|
SI2155674T1
(sl)
|
2007-05-03 |
2011-10-28 |
Suven Life Sciences Ltd |
Aminoalkoksi aril sulfonamid spojine in njih uporaba kot 5-ht6 ligandi
|
|
EP2014656A3
(en)
|
2007-06-11 |
2011-08-24 |
High Point Pharmaceuticals, LLC |
New heteocyclic h3 antagonists
|
|
ATE499099T1
(de)
*
|
2007-07-19 |
2011-03-15 |
Esteve Labor Dr |
Substituierte tetrahydro- chinolinsulfonamidverbindungen, ihre herstellung und ihre verwendung als medikamente
|
|
MX2010003765A
(es)
|
2007-10-26 |
2010-04-30 |
Suven Life Sciences Ltd |
Compuestos de aminoarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6.
|
|
PA8802201A1
(es)
*
|
2007-11-02 |
2009-06-23 |
Abbott Gmbh & Co Kg |
Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
|
|
EP2254564A1
(en)
|
2007-12-12 |
2010-12-01 |
Glaxo Group Limited |
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
|
US20110021538A1
(en)
|
2008-04-02 |
2011-01-27 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US20110034565A1
(en)
|
2008-04-18 |
2011-02-10 |
University College Dublin, National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
CA2726158A1
(en)
*
|
2008-06-11 |
2009-12-17 |
Dana Farber Cancer Institute |
Compounds and compositions useful for the treatment of malaria
|
|
WO2010032257A1
(en)
|
2008-09-17 |
2010-03-25 |
Suven Life Sciences Limited |
Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
|
|
MX2011002884A
(es)
*
|
2008-09-17 |
2011-04-21 |
Suven Life Sciences Ltd |
Compuestos de aril-sulfonamida-amina y su uso como ligandos de 5-ht6.
|
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
|
UA100192C2
(en)
|
2008-11-11 |
2012-11-26 |
УАЙТ ЭлЭлСи |
1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
|
|
KR101073703B1
(ko)
|
2009-04-07 |
2011-10-14 |
한국화학연구원 |
피페라진 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물
|
|
US8343959B2
(en)
|
2009-04-30 |
2013-01-01 |
Abbott Gmbh & Co. Kg |
N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
|
|
WO2010125136A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Abbott Gmbh & Co. Kg |
Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
|
|
CA2759491A1
(en)
|
2009-04-30 |
2010-11-04 |
Abbott Gmbh & Co. Kg. |
Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
|
|
UA107080C2
(uk)
|
2009-04-30 |
2014-11-25 |
|
Сполуки n-феніл(піперазиніл або гомопіперазиніл)бензолсульфонаміду або бензолсульфонілфеніл(піперазину або гомопіперазину), придатні для лікування захворювань, які реагують на модулювання рецептора 5-ht6 серотоніну
|
|
WO2011083487A1
(en)
|
2010-01-05 |
2011-07-14 |
Suven Life Sciences Limited |
Sulfone compounds as 5-ht6 receptor ligands
|
|
AU2011305525B2
(en)
|
2010-09-22 |
2016-08-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
|
WO2012059431A1
(en)
|
2010-11-01 |
2012-05-10 |
Abbott Gmbh & Co. Kg |
Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
|
|
WO2012059432A1
(en)
|
2010-11-01 |
2012-05-10 |
Abbott Gmbh & Co. Kg |
N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
|
|
ES2413911B1
(es)
*
|
2011-12-15 |
2014-05-14 |
Universidad De Zaragoza |
Agente inhibidor de la agregación del peptido beta amiloide.
|
|
EA024767B1
(ru)
|
2012-03-20 |
2016-10-31 |
Адамед Сп. З О.О. |
Сульфонамидные производные бензиламина для лечения заболеваний цнс
|
|
JP6433974B2
(ja)
|
2013-03-14 |
2018-12-05 |
トレロ ファーマシューティカルズ， インコーポレイテッド |
Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
|
|
JP6267334B2
(ja)
|
2013-07-25 |
2018-01-24 |
ユニベルシテット ヤギェウォＵｎｉｗｅｒｓｙｔｅｔ Ｊａｇｉｅｌｌｏｎｓｋｉ |
５−ｈｔ６拮抗薬としてのピロロキノリン誘導体、それらの製造方法および使用
|
|
WO2015158313A1
(en)
|
2014-04-19 |
2015-10-22 |
Sunshine Lake Pharma Co., Ltd. |
Sulfonamide derivatives and pharmaceutical applications thereof
|
|
CN105367473B
(zh)
*
|
2014-08-12 |
2020-02-11 |
广东东阳光药业有限公司 |
吲哚啉类衍生物及其在药物上的应用
|
|
CN105367472B
(zh)
*
|
2014-08-12 |
2020-04-21 |
广东东阳光药业有限公司 |
吲哚啉类衍生物及其在药物上的应用
|
|
CN116850181A
(zh)
|
2015-01-06 |
2023-10-10 |
艾尼纳制药公司 |
治疗与s1p1受体有关的病症的方法
|
|
WO2016201373A1
(en)
|
2015-06-12 |
2016-12-15 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
|
|
AU2016284162A1
(en)
|
2015-06-22 |
2018-02-01 |
Arena Pharmaceuticals, Inc. |
Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
|
|
CA2992518A1
(en)
|
2015-07-15 |
2017-01-19 |
Axovant Sciences Gmbh |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
|
|
CN108926565A
(zh)
*
|
2017-05-26 |
2018-12-04 |
中国科学院上海生命科学研究院 |
五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
|
|
WO2019180176A1
(en)
|
2018-03-21 |
2019-09-26 |
Spherium Biomed, S.L. |
Composition for the treatment of schizophrenia and/or psychosis
|
|
WO2019236757A1
(en)
|
2018-06-06 |
2019-12-12 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the s1p1 receptor
|
|
AU2019310590A1
(en)
|
2018-07-26 |
2021-01-14 |
Sumitomo Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|